Nanjing Vazyme Biotech Co Ltd
SSE:688105
Nanjing Vazyme Biotech Co Ltd
Current Portion of Long-Term Debt
Nanjing Vazyme Biotech Co Ltd
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
N
|
Nanjing Vazyme Biotech Co Ltd
SSE:688105
|
Current Portion of Long-Term Debt
ÂĄ46.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Current Portion of Long-Term Debt
ÂĄ358.8m
|
CAGR 3-Years
57%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
||
Innovent Biologics Inc
HKEX:1801
|
Current Portion of Long-Term Debt
ÂĄ1B
|
CAGR 3-Years
38%
|
CAGR 5-Years
124%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Current Portion of Long-Term Debt
ÂĄ13.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Current Portion of Long-Term Debt
ÂĄ61.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Imeik Technology Development Co Ltd
SZSE:300896
|
Current Portion of Long-Term Debt
ÂĄ15m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Nanjing Vazyme Biotech Co Ltd
Glance View
Nanjing Vazyme Biotech Co., Ltd. is an intriguing player in the biotechnology sector, having carved a niche in the research, development, and production of an array of innovative biological reagents and solutions. Established in the vibrant city of Nanjing, this company stands at the crossroads of science and commerce, offering products that span across PCR reagents, protein engineering, and enzyme solutions. Their expertise is rooted in leveraging cutting-edge molecular biology, allowing the company to cater to a diverse clientele that includes academic research institutions, healthcare providers, and industries that require precise biochemical testing and analysis. Vazyme's growth story is intertwined with the fields of molecular diagnostics and life sciences, industries that have seen rapid advancements and heightened demand, especially in recent years. The company generates revenue predominantly through the sale of high-quality reagents that are essential for the accurate and reliable processing of biological data. By continually incorporating the latest scientific breakthroughs into their products, they ensure that their solutions remain at the forefront of the market. This strategy not only enhances their competitive edge but also solidifies customer loyalty and expands their market presence across the globe, establishing Vazyme as a key contributor to the biotechnology landscape.
See Also
What is Nanjing Vazyme Biotech Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
46.2m
CNY
Based on the financial report for Dec 31, 2023, Nanjing Vazyme Biotech Co Ltd's Current Portion of Long-Term Debt amounts to 46.2m CNY.
What is Nanjing Vazyme Biotech Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 1Y
-21%
Over the last year, the Current Portion of Long-Term Debt growth was -21%.